US vs Germany and Switzerland: US biosimilars market lags with higher prices

Biosimilars/Research | Posted 27/01/2023 comments 0
79 MD002389

In Germany and Switzerland, more biosimilars were marketed and at lower prices than in the US between 2011 and 2020, finds a JAMA Network Open article [1].

More >
FORO LATINOAMERICANO DE ESTA SEMANA
ANVISA V22A14
Guidelines for the regulation of biologicals, biosimilars and radiopharmaceuticals in Brazil
Posted 01/12/2022

ANVISA (Agência Nacional de Vigilância Sanitária), the National Health Survei...

Pegfilgrastim V16B19
Totality of evidence for biosimilar pegfilgrastim Ziextenzo
Posted 09/09/2022

Agarwala et al. have recently published a review on the totality of evidence (ToE)...

Latin America 1638px
Regulatory landscape for biosimilars in Latin America
Posted 09/09/2022

The biosimilar regulatory situation in Latin America varies broadly among the different...

Home/Non‐Biological Complex Drugs
Liposome V15L11

On 4 April 2018, the US Food and Drug Administration (FDA) issued a new draft guidance...

More >